Stason Selegiline HCl 5mg Tablets Recall: Dissolution Stability Issue
Stason Pharmaceuticals recalls 5mg Selegiline HCl tablets due to stability test failure. Affected lots expire June 2017 or July 2018. No remedy specified in official notice.
Recall notice
Stason Pharmaceuticals is recalling Selegiline HCl tablets, USP 5mg 60 count bottle due to an out of specification result for dissolution of stability samples.
Contact the company
What happened, in plain English
Stason Pharmaceuticals is recalling 5mg Selegiline HCl tablets that failed stability testing. This means the tablets may not perform as expected over time, though no immediate harm is reported. The recall affects specific production lots with expiration dates through July 2018. Read more at govinfonow.com/recall/42478-stason-selegiline-hcl-5mg-tablets-recall-dissolution-stability-issue.
Source Summary by GovInfoNow · govinfonow.com/recall/42478-stason-selegiline-hcl-5mg-tablets-recall-dissolution-stability-issue · Updated October 9, 2026 · FDA enforcement record: FDA #D-1479-2016
Cite this page
“Stason Selegiline HCl 5mg Tablets Recall: Dissolution Stability Issue.” GovInfoNow, updated October 9, 2026. https://govinfonow.com/recall/42478-stason-selegiline-hcl-5mg-tablets-recall-dissolution-stability-issue. Based on FDA recall #D-1479-2016 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-1479-2016%22&limit=1).
Why it’s dangerous
The tablets failed stability testing, meaning they may not release the active ingredient properly over time. This could lead to inconsistent medication effects, but the recall does not indicate immediate harm or injury.
Who’s affected
Prescription patients who received Selegiline HCl tablets from Stason Pharmaceuticals in specific lots (14F030-14F032 expiring June 2017, 15G022 expiring July 2018) are affected. Patients using these tablets for Parkinson's disease or other conditions are most at risk.
How to tell if you have this one
Check for the product name 'Selegiline HCl Tablets USP 5mg, 60-count' with NDC 51862-146-06. Look for lot numbers 14F030, 14F031, 14F032 (expiring June 2017) or 15G022 (expiring July 2018).
- Brand
Stason Pharmaceuticals- Category
Drug
What to do — step by step
Check Product Details
Identify the lot number and expiration date on the packaging to confirm if your tablets are affected.
Where it went and when
Where it was distributed
Distributed in North Carolina.
FDA distribution: “North Carolina” States read from FDA’s own wording; “not listed” means the notice does not name it.
States: North Carolina.
Recall timeline
FDA terminated this recall 14 months after the firm started it.
- Firm started the recall
- FDA classified it Class III
- Published in FDA’s Enforcement Report
- FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
Similar recalls
Latest drug recalls
Keep exploring
Where this comes from
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
- Official source: FDA Recall #D-1479-2016 (August 23, 2016) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-1479-2016 to see it in context.
- Plain-language summary written by qwen3:4b on October 9, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
- GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.